Courtagen, AGBL enter exclusive distribution agreement for clinical tests
Published on November 15, 2012 at 8:17 AM
Courtagen Life Sciences Inc. announced today they have signed an exclusive strategic distribution agreement with the Alliance Global Group (AGBL) to help clinicians in emerging markets diagnose and manage a number of genetically based disorders. Courtagen's test menu currently offers clinical tests for mitochondrial disorders (mtSEEK™ and nucSEEK™) and a newly released panel for epilepsy and seizure (epiSEEK™). Courtagen plans to add a number of key tests for other important neurological disorders.
“We are pleased to enter into this agreement with Courtagen”
"Building this relationship with AGBL is a critical component of Courtagen's international business expansion," said Brian McKernan, CEO, Courtagen Life Sciences, Inc.
Courtagen's CLIA Laboratory genetic tests use next generation sequencing (NGS) technology, propriety bioinformatics platform, ZiPhyr™ and state of the art analytic capabilities to accurately sequence patient's DNA and translate the sequence data into highly useful, clinically relevant information for physicians. Additionally, Courtagen's protein diagnostics division offers decentralized testing of protein biomarker to simplify pre-clinical and clinical trial protocols.
"We are pleased to enter into this agreement with Courtagen," said Dr. Tamer Degheidy, CEO of Alliance Global. "Courtagen's portfolio of genetic tests will certainly have a positive impact on patients' diagnosis and management in markets covered by our group."
Alliance Global Group (AGBL)